Sign in
Taking peoplePhase 2

Tocilizumab compared with adalimumab for severe eye inflammation in Behçet's disease

Compares tocilizumab with adalimumab for severe uveitis in adults with Behçet's disease.

Key facts

Who runs it
Assistance Publique Hopitaux De Paris
Where
France26 sites in 1 countryChoose a country to see its sites
Registry title
UVB: treatment of UVeitis in Behçet’s diseases with biologic
Status
Recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
25 Apr 2024
Expected to end
25 Apr 2028
Type of study
Interventional
Record updated
11 July 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Behçet's disease who have severe eye inflammation (uveitis) that threatens their sight. It compares adalimumab with tocilizumab.

Age
18 years and older
Sex
All sexes
Disease stage
Non-infectious intermediate, posterior or pan-uveitis in at least one eye that threatens sight. This means a drop of 2 lines in visual acuity on a 10/10 scale, and/or inflammation of the retina (macular oedema and/or retinal vasculitis).
Earlier treatment
No anti-TNF and/or Tocilizumab therapy within 1 month before joining. Azathioprine, mycophenolate mofetil or methotrexate must be stopped before the first trial dose. No live vaccine within 30 days before joining.
Biomarker or test result
Negative TB test within 12 weeks before joining. People with a positive IGRA test can join if there is no sign of active TB and they agree to TB preventive treatment.

Main reasons for not taking part

  • Uveitis caused by infection or by something other than Behçet's disease
  • Active tuberculosis, untreated past tuberculosis or severe infection
  • Positive test for HIV, hepatitis B or hepatitis C
  • Pregnant or breastfeeding women
  • Cancer within 5 years, multiple sclerosis, or severe heart, kidney or liver failure

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Age >= 18 at Inclusion
  • Affiliation to a social security system. Patients affiliated to universal medical coverage (CMU) are eligible for the study
  • Provide written, informed consent prior to the performance of any study-specific procedures
  • Diagnosis of Behçet’s disease according to the International Criteria for Behçet's Disease (ICBD) (see appendix 18.2) or history of aphtosis
  • Diagnosis of non-infectious intermediate, posterior-, or pan-uveitis in at least one eye fulfilling the International Study Group Classification Criteria (Standardization of Uveitis Nomenclature [SUN] criteria) of posterior, or pan- uveitis
  • Sight threatening uveitis defined according to the validated international definition as 2 lines of drop in visual acuity on a 10/10 scale, and/or retinal inflammation (macular oedema and/or retinal vasculitis)
  • Chest X-ray (postero-anterior and lateral) or CT-scanner results within 12 weeks prior to Inclusion with no evidence of active Tuberculosis, active infection, or malignancy
  • For female subjects of child-bearing potential (premenopausal female capable of becoming pregnant), a negative serum pregnancy test (plasmatic or urinary)
  • For subjects with reproductive potential, a willingness to use contraceptive measures adequate to prevent the subject or the subject’s partner from becoming pregnant during the study and 3 and 5 months after stopping therapy for tocilizumab and adalimumab, respectively
  • Negative TB test obtained within 12 weeks prior to inclusion. A potential subject with a positive interferon-gamma release assay (IGRA) (e.g., QuantiFERON®-TB Gold or T-spot TB® Test) is eligible if her/his chest X-ray does not show evidence suggestive of active TB disease and there are no clinical signs and symptoms of pulmonary and/or UVB protocol, version 5.0 of 02/04/2024 31/76 This document is the property of DRCI/AP-HP. All reproduction is strictly prohibited extra-pulmonary TB disease. These subjects with a latent TB infection who have not already received a prophylactic TB treatment must agree in advance to complete such a treatment course. The treatment should be started at the latest at inclusion

Who cannot take part

  • Treatment with anti-TNF and/or Tocilizumab therapy within 1 month prior to inclusion
  • Patient on azathioprine, mycophenolate mofetil, or methotrexate at the time of inclusion (these drugs must be withdrawn prior to receiving the tocilizumab or adalimumab dose on Day 0)
  • Any live (attenuated) vaccine within 30 days prior to inclusion
  • Positive HIV antibody and/or positive hepatitis B surface antigen and/or positive hepatitis C RNA, results obtained within 1 month prior to inclusion
  • Infectious uveitis, masquerade syndromes, or uveitis due to causes other than BD uveitis
  • History of intestinal ulceration or diverticulitis
  • Stage III and IV New York Heart Association (NYHA) cardiac insufficiency
  • Active tuberculosis or history of untreated tuberculosis and/or severe infection
  • History of malignancy within 5 years prior to Inclusion other than carcinoma in situ of the cervix, non-metastatic squamous or basal cell carcinoma of the skin
  • History of severe allergic or anaphylactic reactions to monoclonal antibodies
  • History of multiple sclerosis and/or demyelinating disorder
  • Hypersensitivity to the active substance or an excipient of the IMP or the auxiliary medicine
  • Active or suspected ocular infection
  • Infection oculaire active suspectée
  • Laboratory values assessed during Inclusion: a. Neutrophil < 1.0 x 10^3/mm3 ; b. Platelet count < 80x 10^3/mm3 ; c. ASAT or ALAT > 5 ULN
  • Severe renal (Glomerular filtration rates (GFR) <30ml/min) or liver insufficiency (prothrombin <50% without other causes)
  • Known porphyria
  • Breastfeeding and pregnant women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To assess the benefit of tocilizumab comparatively to that of adalimumab in sight-threatening Behçet’s disease uveitis at week 16.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
UVB : Multicenter, randomized, prospective trial comparing the Efficacy and Safety of Adalimumab to that of Tocilizumab in severe uveitis of Behçet’s disease
Plain-language title
Tocilizumab compared with adalimumab for severe eye inflammation in Behçet's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
11 July 2025